In a single day, the talk on the Street has zeroed in on one stock, oncology-focused cell therapy company Adaptimmune Therapeutics (ADAP). Following its presentation of promising data at the 38th annual J.P. Morgan Healthcare Conference, shares took off, posting a whopping 200% one-day gain.The data revealed that its MAGE-A4 (ADP-A2M4 and next-generation ADP-A2M4CD8) and AFP (ADP-A2AFP) therapies, part of its SPEAR T-cell platform, demonstrated initial solid tumor responses in four indications: gastro-esophageal junction, head and neck, liver cancers and melanoma.“These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a …read more
Source:: Yahoo Finance
